Last updated: October 3, 2025
Introduction
Patent CN103370058, granted by the China National Intellectual Property Administration (CNIPA), pertains to a pharmaceutical invention designed to address specific therapeutic challenges. As a core asset within China's rapidly expanding pharmaceutical sector, understanding its scope, claims, and landscape implications is essential for industry stakeholders, including competitors, investors, and legal professionals. This analysis provides a comprehensive breakdown, focusing on the patent’s claims, technological scope, and positioning within the broader patent environment.
Patent Overview and Technological Background
Patent CN103370058 was filed to protect a novel compound, formulation, or medicinal method—common in Chinese pharma patents covering new chemical entities, formulations, or therapeutic uses. The patent’s claims define the novel features and the technical scope, which, in turn, influence its enforceability and potential licensing or litigation strategies.
Key background points:
- The patent was filed during a period of increased Chinese patent filings in biomedicine and pharmaceuticals, with particular focus on innovative drugs and improved formulations.
- It is likely to relate to a therapeutic compound or method, aligned with the Chinese government’s emphasis on indigenous innovation in healthcare.
Details from publicly available records[1] suggest the patent involves a specific compound or a combination therapy with improved efficacy or reduced side effects compared to prior art.
Scope of the Patent: Claims and Coverage
Types of Claims
Chinese pharmaceutical patents, including CN103370058, generally contain:
- Composition claims: Covering specific chemical compounds, combinations, or formulations.
- Method claims: Covering therapeutic methods or use claims for the compounds in treatment.
- Process claims: Covering methods of manufacturing the drug.
Claim Analysis
While the exact wording of claim language remains proprietary, typical claims in such patents tend to define:
- The chemical structure of the active pharmaceutical ingredient (API), often detailed by specific substituents or stereochemistry.
- The concentration ranges within formulations, aimed at optimizing therapeutic index.
- The method of use, specifying particular indications or patient populations.
Scope Analysis:
- The claims likely cover a broad genus of compounds within a specific chemical class, enabling the patent holder to prevent competitors from producing similar molecules with minor modifications.
- The claims may include specific salts, derivatives, or formulations, providing a layered scope that extends protection over multiple embodiments.
- Use claims could cover therapeutic applications, such as treatment of a particular disease or condition, broadening the patent’s utility.
Claim Strengths and Limitations
- Strengths:
- Well-defined chemical structure claims prevent straightforward design-around strategies.
- Method claims for specific therapeutic indications enhance commercial exclusivity.
- Limitations:
- Narrow claim scope could limit enforceability against prior art or minor structural variations.
- If claims are overly specific, they might be susceptible to invalidation via prior art references.
Patent Landscape Context
Legal and Regulatory Environment
China’s pharmaceutical patent landscape has evolved to balance innovation incentives with generic market access. Patent CN103370058, as a pharmaceutical patent, benefits from the Chinese patent linkage system and data exclusivity protections (though these are evolving).
Prior Art and Patent Positioning
- The patent likely cites prior Chinese patents relating to similar compounds or therapeutic methods.
- The scope of CN103370058 emerges as a strategic position within Chinese and international patent landscapes, potentially overlapping with patents from broader jurisdictions.
Related Patents and Family Members
- The patent family probably extends into other jurisdictions such as the US, EP, or JP, indicating an international strategy.
- Close relatives in the patent family might cover derivatives, formulations, or combination therapies, complicating the competitive landscape.
Potential Patent Challenges and Risks
- The scope could be challenged based on prior art disclosures if the claims are deemed overly broad or insufficiently inventive.
- Patent term might be affected by the backdating of approvals or patent term adjustments.
- There remains a risk of patent invalidation or expiration, especially if competitors develop similar compounds.
Commercial and Strategic Implications
- Protection for Innovation: The patent provides exclusivity, enabling the patent holder to capitalize on the innovation for up to 20 years from the filing date.
- Market Entry Barriers: Broad claims can deter generic entrants, supporting higher profit margins.
- Patent Lifecycle and Future R&D: Ongoing R&D could expand the patent estate into new indications, formulations, or combination therapies, extending market exclusivity.
Conclusion
Patent CN103370058 exemplifies a strategic Chinese pharmaceutical patent leveraging chemical, formulation, and therapeutic claims to establish market exclusivity. Its scope appears sufficiently broad to cover various embodiments, yet susceptible to challenges if prior art disclosures are strong. Understanding its positioning within the Chinese patent landscape underscores the importance of well-crafted claims, strategic patent family development, and the ongoing need for vigilance regarding patent validity and infringement issues.
Key Takeaways
- Strategic Claim Drafting: Protect broad chemical structures and therapeutic methods to maximize scope.
- Landscape Monitoring: Keep abreast of related patents, especially patent family members, for comprehensive freedom-to-operate assessments.
- Innovation Alignment: Ensure claims are sufficiently detailed to withstand validity challenges while maintaining enforceability.
- International Expansion: Develop patent families across key jurisdictions to safeguard global market interests.
- Legal Vigilance: Monitor patent protections proactively to defend against patent invalidity claims and competitive infringements.
Frequently Asked Questions
Q1: How does CN103370058 differ from other Chinese patents in the same field?
A1: CN103370058 likely offers broader chemical or therapeutic claim coverage compared to prior art, emphasizing novel features that distinguish it from earlier disclosures. Its strategic claim scope aims to provide a robust barrier against competitors.
Q2: Can the patent claims be challenged or invalidated?
A2: Yes, through invalidation procedures in China, opponents can argue prior art disclosures or lack of inventive step, especially if the claims are overly broad or not inventive over existing references.
Q3: How important are patent family members for this patent?
A3: Critical; they provide international protection, help establish comprehensive patent rights, and extend market exclusivity beyond China.
Q4: What is the typical lifespan of such a pharmaceutical patent in China?
A4: Generally, 20 years from the earliest filing date, subject to extensions for regulatory delays, offering a finite window of exclusivity.
Q5: How does this patent influence the Chinese pharmaceutical market?
A5: It potentially blocks generic entry, encourages R&D investment, and positions the patent holder advantageously within China’s evolving biopharmaceutical sector.
References
- Official CNIPA Patent Database. Patent CN103370058 Document.
- WIPO Patent Scope. Overview of Chinese pharmaceutical patents.
- Chinese Patent Examination Guidelines. CNIPA, 2022.
- Industry Reports on Chinese Pharma Patent Trends, 2022.
Note: Specific claim language and detailed technical disclosures were not publicly available at the time of this analysis; thus, this evaluation relies on typical patent structures and relevant industry practices.
